




COURT MATTER.
Bid Evaluation Report


1. Name of Procuring Agency: Program Manager, Prevention & control of Hepatitis Program Sindh Hyd
2. Tender Reference No: PD/HCPs/HYD(Tender 2014-15)/-2175/82 dated:8-5-2015
3. Tender Description/Name of work/item: Inj: Pegylated Interferon Alfa 2a
4. Method of Procurement: Single stage Two Envelops Bidding Procedure
5. Tender Published: Daily Express Tiribune(English) dated 13-05-2015 , Daily Ibrat (Sindhi) dated: 13-05-2015 and Daily Express (Urdu) dated: 13-05-2015 Sindh Public Procurement Regulatory Authority Government of Sindh Karachi on dated:12-05-2015 vide his SPPRA S. No24127 and SPPRA ID No. 1575219738
6. Total Bid documents Sold; 04 Nos.
7. Total Bids Received: 02. (For Inj: Pegylated Interferon Alfa 2a with Cap Ribavirin 400mg).
8. Technical re-evaluate Bid Opening date: (if applicable) 21-11-2015(Re-evaluation of Technical Bid done as decision passed by Honourable High Court of Sindh in High Court appeal No. 209 & 238 of 2015(copy enclosed)
9. No. of Bid technically qualified (if applicable): 01 only Inj: Pegylated Interferon Alfa 2a
10. Bid(s) Rejected: one (disqualified)
11. Financial Bid Opening date: 25-11-2015
12. Bid Evaluation Report:


S No	Name of Firm or Bidder	Cost offered by the Bidder	Ranking in terms of cost	Comparison with Estimated cost	Reasons for acceptance/rejection	Remarks
0	1	2	3	4	5	6
1.	M/s Lab Link Enterprises Hyderabad	As per comparative statement	As per comparative statement	estimated	As per tender evaluation criteria	
2.	M/s A.J.M Pharma Karachi	-	-	-	Not as per Bid evaluation criteria	Disqualified



Mr. Aziz Mustafa Shaikh
Assistant Accounts Officer
District Accounts Officer
Hyderabad
Member



Mr. Habib-ul-Islam
Representative of Finance
Department
Government of Sindh
Karachi
Member


Dr. Bikha Ram Devrajani
Professor of Medicine
/Hepatologist
LUMHS, Jamshoro
Member


Dr. Bader Faiyaz Zuberi
Professor of Medicines and
Provincial Hepatologist
Civil Hospital Karachi
Member


Dr. Abdul Khaliq Shaikh
Program Manager
Prevention & Control of Hepatitis
(Chief Minister Initiative) Sindh
Hyderabad
Member/Secretary



Dr. M. Sabir Memon
Additional Secretary (PM & I)
Government of Sindh Health
Department
Karachi
Member



Dr. Hassan Murad Shah
Director General
Health Services Sindh Hyderabad
Chairman


COURT MATTER


COMPARATIVE STATEMENT FOR PROCUREMENT OF (ALFA-2A INJECTION PEGYLATED WITH CAP RIBAVIRIN 400MG) FOR THE YEAR 2014-2015 TO COMPLY WITH THE ORDERS PASSED ON 13-11-2015 BY THE HONOURABLE HIGH COURT OF SINDH IN HIGH COURT APPEAL NO.209 & 238 OF 2015 HELD ON 25-11-2015


S.#	Description / Name of items	M/s. Lab Link Enterprises Hyderabad						
1	Inj: Pegelated Interferon Alfa2a 180mcg With Cap Ribavirin 400mg (21 (Cap)	Rs.5675/- M/s Roche Pakistan Limited						
<p>REMARKS:- As per High Court decision passed in the High Court appeal No. 209 & 238 of 2015 decision passed on 13-11-2015 the Manufacturer M/s Roche Pakistan has offered 12.5% discount on quoted rate in the said Tender</p> <table border="0"> <tr> <td>1. Quoted</td> <td>Rs. 5675/-</td> </tr> <tr> <td>2. 12.5% discount</td> <td>Rs. 709.37</td> </tr> <tr> <td>Net rate</td> <td>Rs. 4965.63</td> </tr> </table>			1. Quoted	Rs. 5675/-	2. 12.5% discount	Rs. 709.37	Net rate	Rs. 4965.63
1. Quoted	Rs. 5675/-							
2. 12.5% discount	Rs. 709.37							
Net rate	Rs. 4965.63							



Mr. Aziz Mustafa Shaikh
Assistant Accounts Officer
District Accounts Officer
Hyderabad
Member



Dr. Bader Faiyaz Zuberi
Professor of Medicines and Provincial
Hepatologist
Civil Hospital Karachi
Member



Habib-ul-Islam
Representative of Finance Department
Government of Sindh
Karachi
Member


Dr. Abdul Khaliq
Program Manager
Prevention & Control of Hepatitis (Chief
Minister Initiative) Sindh Hyderabad
Secretary / Member


Dr. Hassan Murad Shah
Director General
Health Services Sindh Hyderabad
Chairman


Dr. Bikha Ram Devrajani
Professor of Medicine/Hepatologist, LUMHS,
Jamshoro
Member


Dr. M. Sabir Memon
Additional Secretary (PM & I)
Government of Sindh Health Department
Karachi
Member



OFFICE OF THE PROGRAMME MANAGER
HEPATITIS PREVENTION & CONTROL PROGRAM, SINDH
(CHIEF MINISTER'S INITIATIVE) @
DIRECTORATE GENERAL HEALTH SERVICES SINDH, HYDERABAD
PHONE NO. 022-2671693 FAX NO. 022-2671696.
www.hpcp.com.pk



Meeting regarding Opening of financial Bids by the Procurement committee to comply with the orders passed by the Honourable High Court of Sindh in High Court Appeal No.209 & 238 of 2015 on 13-11-2015 for reevaluation(ALFA-2A Injection) of Technical Bid/proposals of with held procurement held on 25-11-2015 at 03.00 P.M in the committee room of Directorate General Health Services Sindh Hyderabad.

SR.NO.	NAME	DESIGNATION	SIGNATURE	POSITION
01	Dr. Hassan Murad Shah	Director General Health Services Sindh Hyderabad		Chairman
02	Dr. M. Sabir Memon	Additional Secretary (PM&I) Govt: of Sindh Health Department, Karachi		Member
03	Dr. Abdul Khaliq Shaikh	Program Manager, Prevention and Control of Hepatitis (Chief Minister's Initiative) Sindh Hyd		Secretary
04	Dr. Bader Faiyaz Zuberi,	Professor of Medicines and Provincial Hepatologist Civil Hospital Karachi		Member
05	Dr. Bikha Ram Devrajani	Professor of Medicines / Hepatologist LUMHS Jamshoro		Member
06	Mr. Habib-ul-Islam	Representative of Finance Department, Government of Sindh Karachi		Member
07	Mr. Aziz Mustafa Shaikh	Assistant Account Officer, District Accounts Office Hyderabad		Member

COURT MATTER
MINUTES OF THE MEETING OF THE PROCUREMENT COMMITTEE FOR OPENING OF
FINANCIAL PROPOSALS OF INJ: PEGYLATED INTERFERON ALFA2A WITH CAP
RIBAVIRIN 400MG (21 CAP WITH EACH INJ:) HELD ON 25-11-2015 AT 3.00 PM IN THE
COMMITTEE ROOM OF DIRECTORATE GENERAL HEALTH SERVICES SINDH HYDERABAD.

The meeting of the Procurement Committee for opening of financial proposal for procurement of Inj: Pegylated Interferon Alfa 2a to comply with the order passed on 13-11-2015 by the Honourable High Court of Sindh in High Court appeal No. 209 & 238 of 2015 held on 25-11-2015 at 3:00 pm in the committee room of Directorate General Health Services Sindh Hyderabad. The procurement committee open the financial proposal in presence of bidder of Inj: Pegylated Interferon Alfa 2a.

Letters have been issued to the qualified and disqualified firms.


The rate quoted by M/s Lab Link Enterprises Hyderabad publically announced before bidder.

The M/s Lab Link Enterprises Hyderabad has quoted the Inj: Pegylated Interferon Alfa 2 180mcg of M/s Roche Pakistan Limited. As per decision of the Honourable High Court the Manufacturer M/s Roche Pakistan Limited offer 12.5% discount on quoted rates, hence the financial Bid of M/s Lab Link Enterprises Hyderabad is opened by the procurement committee.

- 01 Dr. Hassan Murad Shah
Director General Health Services Sindh
Hyderabad
- 02 Dr. M. Sabir Memon
Additional Secretary (PM & I)
Government of Sindh Health Department
Karachi
- 03 Dr. Abdul Khaliq Shaikh
Program Manager
Prevention & Control of Hepatitis (Chief Minister Initiative) Sindh
Hyderabad
- 04 Dr. Bader Faiyaz Zuberi
Professor of Medicines and Provincial Hepatologist
Civil Hospital Karachi
- 05 Dr. Bikha Ram Devrajani
Professor of Medicine/Hepatologist
LUMHS, Jamshoro
- 06 ~~Dr.~~ Habib-ul-Islam
Representative of Finance Department
Government of Sindh
Karachi
- 07 Mr. Aziz Mustafa Shaikh
Assistant Accounts Officer
District Accounts Officer
Hyderabad e


Chairman


Member


Secretary/Member


Member



Member









Member


Member

HEPATITIS B & C MEDICINE
(Inj Pegylated interferon Alfa 2a with Cap
Ribavirin 400mg)
ATTENDANCE SHEET.

The sealed financial Bid for Procurement of of Inj: Pegylated Interferon Alfa 2a with cap Ribavirin 400mg was open in our presence on 25.11.2014 to comply with the orders passed by the Honourable High Court of Sindh in High Court Appeal No.209 & 238 of 2015 on 13-11-2015 @ appropriate time. The procedure adopted is transparent and we are satisfied.

SR.NO.	NAME OF FIRM	CONTRACT #'	SIGNATURE
01	M/s Lab Link Entr: Hyd	03028371295	

  
  
 25/11/15


ORDER SHEET
IN THE HIGH COURT OF SINDH, KARACHI
HIGH COURT APPEAL No. 209 OF 2015
HIGH COURT APPEAL No. 238 OF 2015

Dated _____ Order with signature of Judge _____

HIGH COURT APPEAL No. 209 of 2015

1. For hearing of Main Case
2. For Order on CMA No. 1872/2015
3. For Order on Nazir's Report dated 03.10.2015
4. For Order on Nazir's Report dated 19.10.2015

HIGH COURT APPEAL No. 238 of 2015

1. For Orders on CMA No. 2447/2015
2. For Orders on CMA No. 2448/2015
3. For hearing of Main Case
4. For Order on CMA No. 2449/2015

13.11.2015

Mr. Hyder Ali Advocate for the Appellant in H.C.A. No. 209/2015

Mr. Faisal Siddiqui Advocate for the Respondent No.1

Mr. Mukesh Kumar AAG

Dr. Abdul Khaliq, Program Manager, Hepatitis Control Program

Mr. Ch. Mamoon, Advocate for the Respondent No.6

M/s. Getz Pharama (Pvt.) Limited after rejection of their technical bid by the Government of Sindh filed a suit in which an interim order restraining the Government of Sindh from opening financial bid was passed on 09.06.2015 which order has been impugned in these appeal by the Government of Sindh as well as M/s. Roche Pakistan Limited a bidder. Consequently, after hearing all concern vide Order dated 24.08.2015 by consent we have called report from various Senior Doctors regarding safety, efficacy and potency of the Peg-interferon Alpha-2A subject matter of the procurement.

In consequent to the Consent Order dated 24.08.2015, report has been submitted by Dr. Zaigham Abbas, Prof. Ghyas-un-Nabi and Prof. Abdur Rauf Memon regarding the safety efficacy and potency of the Peg-interferon Alpha-2A manufactured by M/s. Getz Pharma (Pvt.) Limited, Roche Pakistan Limited and Pooyesh Daron Company Tahrán, Iran. Since the main contestant in the proceeding being M/s. Getz Pharma and Roche Pakistan Limited, consequently, we in presence of their counsel have gone through the report submitted by the panel of Doctors.

Dr. Zaigham Abbas has shown his inability to give report regarding head to head trial comparing safety efficacy and potency of the Peg-interferon sold by either party in the country, Dr. Abdul Rauf Memon has in his report stated that all three drugs are pegylated interferon Alfa 2-A and registered with the Ministry of Health and are expected to have same safety, efficacy and potency. He stated to have no experience of use of Iranian pegylated interferon, whereas, in respect of Roche Pakistan Limited and Getz Pharma (Pvt) Limited his comments are reproduced:-

"I have used Roche pegylated interferon which is also used in Europe and USA for several years with desirable results. I have used Getz pegylated interferon with lesser experience and probably similar results."

The third Member of the panel i.e. Prof. Ghyas-un-Nabi has given a very extensive report in respect of drug manufactured by all three companies which is reproduced below:-

"Pegylated Interferon alpha 2a 180 mcg previously marketed as Pegasys by Roche Pharma Limited, now available with the name of Ropergra has been extensively studied and used at international and national levels and its safety, efficacy and potency is consider to be gold standard.

Pegylated Interferon alpha 2a 180 mcg marketed by Pooyesh Daron Co, Tehran, Iran with the name of Pegaferon has been studied and used extensively in Iran and Pakistan and no concern about safety, efficacy and potency have been raised. In the clinical studies / Phase IV publications in various scientific journals, its safety, efficacy and potency has been found comparable to the product mentioned in paragraph number 4.

Pegylated Interferon alpha 2a 180 mcg marketed by Getz Pharma (Pvt) Limited with the name of Unipeg is registered and available in Pakistan only and has been used by number of practitioners. Various Phase IV clinical studies have been presented as abstracts at National and International meetings and no concern about safety, efficacy and potency have been shown in any of these studies. No publication has been made in any of the medical journals in support of safety, efficacy and potency of this product.

There has been no head to head comparatives trials comparing these products having biosimilar molecules at any time have been done which may enable me to guide the court to compare the relative safety, efficacy and potency of these three products."

Perusal of the report does not from any angle reflects that the drug manufactured by M/s. Getz Pharma is spurious or not safe for human consumption or which could be rejected for want of safety, efficacy and potency, however, the product of Roche as it appears from the report is being used internationally with desirable results, has been extensively studied and used at international and national levels

and as stated by Dr. Ghyas-un-Nabi its safety, efficacy and potency could be considered to be of gold standard and for this reason it may have an edge on the product of M/s. Getz Pharma and for this reason perhaps its market price appears to be almost 75% more than the price of Getz Pharma drug. Both companies viz. Roche Pakistan Limited and Getz Pharma (Pvt.) Limited keeping in view that the drugs are to be used for the poor and deprived class have voluntarily offered to reduce their prices (which they have quoted and are yet to be opened) by 12.5% and 20% respectively.

Both the learned counsel have earnestly submitted before us that the litigation is not for profit earning, as the prices quoted are so low and further reduced, hardly meets the cost. Mr. Siddiqui contends that rejection of M/s. Getz Pharma's technical bid is a stigma on their product which has compelled the Respondent to approach this Court, however, the most important aspect which needs to be considered is that the interim order passed in these proceedings had adversely effected poor and deprived class specially those incarcerated in prisons for whose curement the instant injections are being procured.


In these circumstances, the technical committee of the Respondent would reconsider the order rejecting the technical bid of M/s. Getz Pharma (Pvt.) Limited keeping in view the observations made hereinabove and if they find them entitled would open their financial bid as well. Notwithstanding, if their technical bid is still rejected the financial bid of the remaining bidders would be opened and procurement order would be placed forthwith. The appeals in above terms are allowed to the extent as above and by vacating the ad-interim order passed by the learned Single Judge restraining the procurement process. However, this order is without prejudice to the rights of the Respondent M/s. Getz Pharma (Pvt.) Limited to pursue its course in accordance with law.


S. M. Javed Anjum
S. M. Javed Anjum
JUDGE
JUDGE


Amjad/PA


BID EVALUATION REPORT FOR PROCUREMENT OF INJ: PEGYLATED INTERFERON ALFA2a WITH CAP RIBAVIRIN 400MG (21 CAP WITH EACH INJ.) FOR THE YEAR 2014-2015 (Creative)


S.#	Evaluation Criteria	M/s Lab Link Enterprises Hyderabad		M/s A.J.M Pharma Karachi	
		Yes	No	Yes	No
1	Registration with Ministry of Health Govt. of Pakistan	Y	-	Y	-
2	shelf life should be 80%	Y	-	Y	-
3	Fulfillment of the tender conditions of ITB clause 8 & 10	Y	-	Y	-
4	Manufacturer Authorization on prescribed proforma	Y	-	Y	-
5	GMP certification of Manufacturer / copy of certificate	Y	-	Y	-
6	A certificate that the prices quoted are not higher or more than market price.	Y	-	Y	-
7	Provision of sample(s) along with Lab. Test Report (from National Control Laboratory for Biological, MoH, Govt. of Pakistan)	Y	-	Y	-
8	Certificate of Analysis from Manufacturer	Y	-	Y	-
9	Bill of landing / Bill of Entry	Y	-	Y	-
10	Proof of financial soundness certificate from schedule Bank about 200 (M) Last three years	Y	-	Y	-
11	Bank Statement last 3 years	Y	-	Y	-
12	Audit Reports of three years (2011-2012, 2012-2013 and 2013-2014)	Y	-	Y	-
13	Proof of General Sales Tax paid during the last three years	Y	-	Y	-
14	Proof of Income Tax paid during the last three years	Y	-	Y	-
15	Proven Track Record last three years of the firm	Y	-	Y	-
16	Original Price List of the Manufacturer/Importer.	Y	-	Y	-
17	Copy of Professional Tax Certificate current year	Y	-	Y	-
18	Copy of Chamber & commerce Industries certificate current year	Y	-	Y	-
19	Physical proof of availability of cold chain of participated bidders for cold chain items.	Y	-	Y	-
20	Valid Drugs sales license of supplier/ Bidder	Y	-	Y	-
21	Original purchase tender receipt.	Y	-	Y	-
22	EMA/WHO/DRAP/FDA approved	Y	-	Y	-
23	SVR Data published in reputable Journals	Y	-	Y	-
		Qualified		Disqualified	


 **Mr. Aziz Mustafa Shaikh**
 Assistant Accounts Officer
 District Accounts Officer
 Hyderabad
 Member


 **Dr. Bader Fayez Zuberi**
 Professor of Medicines and
 Provincial Hepatologist
 Civil Hospital Karachi
 Member

 **Dr. Bikha Rani Devrajani**
 Professor of Medicine/Hepatologist
 LUMHS, Jamshoro
 Member

 **Dr. M. Sabir Memon**
 Additional Secretary (PM & I)
 Government of Sindh Health Department
 Karachi
 Member

 **Dr. Abdul Khaliq Shaikh**
 Program Manager
 Prevention & Control of Hepatitis(Chief
 Minister Initiative) Sindh Hyderabad
 Secretary / Member

 **Dr. Huzeefa Murad Shah**
 Director General
 Health Services Sindh Hyderabad
 Chairman



OFFICE OF THE PROGRAMME MANAGER
HEPATITIS PREVENTION & CONTROL PROGRAM, SINDH
(CHIEF MINISTER'S INITIATIVE) @
DIRECTORATE GENERAL HEALTH SERVICES SINDH, HYDERABAD
PHONE NO. 022-2671693 FAX NO. 022-2671696.
www.hpcp.com.pk



Meeting regarding Technical evaluation of Bids by the committee to comply with the orders passed by the Honourable High Court of Sindh in High Court Appeal No.209 & 238 of 2015 on 13-11-2015 for reevaluation (ALFA-2A Injection) of Technical Bid/proposals of with held procurement held on 21-11-2015 at 12.00 noon in the office of Program Manager, Prevention and Control of Hepatitis (Chief Ministers Sindh) Hyderabad.

SR.NO.	NAME	DESIGNATION	SIGNATURE	POSITION
01	Dr. Hassan Murad Shah	Director General Health Services Sindh Hyderabad		Chairman
02	Dr. M. Sabir Memon	Additional Secretary (PM&I) Govt: of Sindh Health Department, Karachi		Member
03	Dr. Abdul Khaliq Shaikh	Program Manager, Prevention and Control of Hepatitis (Chief Minister's Initiative) Sindh Hyd		Secretary
04	Dr. Bader Faiyaz Zuberi,	Professor of Medicines and Provincial Hepatologist Civil Hospital Karachi		Member
05	Dr. Bikha Ram Devrajani	Professor of Medicines / Hepatologist LUMHS Jamshoro		Member
06	Dr. Habib-ul-Islam	Representative of Finance Department, Government of Sindh Karachi		Member
07	Mr. Aziz Mustafa Shaikh	Assistant Account Officer, District Accounts Office Hyderabad		Member

MINUTES OF THE MEETING OF THE PROCUREMENT COMMITTEE FOR RE-EVALUATION OF TECHNICAL BID/ PROPOSALS (ALFA-2A INJECTION PEGYLATED WITH CAP RIBAVIRIN 400MG) TO COMPLY WITH THE ORDERS PASSED ON 13-11-2015 BY THE HONOURABLE HIGH COURT OF SINDH IN HIGH COURT APPEAL NO.209 & 238 OF 2015 HELD ON 21-11-2015 IN THE OFFICE OF THE PROGRAM MANAGER, PREVENTION AND CONTROL OF HEPATITIS PROGRAM SINDH HYDERABAD

The meeting of the Technical Committee for re-evaluation of Technical Bid/proposals (Alfa-2a Injection pegylated with Cap Rbavirin 400mg) to comply with the order passed on 13-11-2015 by the Honourable High Court of Sindh in High Court appeal No. 209 & 238 of 2015 held on 21-11-2015 in the office of the Program Manager, prevention and Control of Hepatitis Program (Chief Minister's initiative) Sindh Hyderabad for finalization of with held procurement.

The Procurement Committee constituted by the Government comprising of the following officers vide Government Notification bearing No. SO(PM&I)2-1/2014/PP-08/(HCP) dated:17-12-2014 under the Chairman of Special Secretary(P.H)

The Government of Sindh Health Department, Karachi replaced the Special Secretary (P.H)(Chairman) with Director General Health Services Sindh Hyderabad vide bearing No. SO (PM&I)2-1/2014/PP-08/(HCP) dated:20-11-2015 due the post of Special Secretary is lying vacant since long.

01 Dr. Hassan Murad Shah
Director General Health Services Sindh Hyderabad.

Chairman

02 Dr. M. Sabir Memon
Additional Secretary (PM & I)
Government of Sindh Health Department
Karachi

Member

03 Dr. Abdul Khaliq Shaikh
Program Manager
Prevention & Control of Hepatitis (Chief Minister Initiative) Sindh Hyderabad

Secretary/Member

04 Dr. Bader Faiyaz Zuberi
Professor of Medicine and Provincial Hepatologist
Civil Hospital Karachi

Member

05 Dr. Bikha Ram Devrajani
Professor of Medicine/Hepatologist
LUMHS, Jamshoro

Member

06 ~~Mr.~~ Habib-ul-Islam
Representative of Finance Department
Government of Sindh
Karachi

Member

07 Mr. Aziz Mustafa Shaikh
Assistant Accounts Officer
District Accounts Officer
Hyderabad

Member

The Procurement Committee re-evaluated the Technical Proposals of Inj: Pegylated Interferon Alfa 2a. During the evaluation of technical proposal of Inj: Pegylated Interferon Alfa 2a of technical proposal, the following firms have been qualified /disqualified for below mentioned reason.

Technical Evaluation Report of Inj: Pegylated Interferon Alfa 2a, detail is as under

In view of decision of honourable high court and statements given by three eminent consultants, the technical committee is of opinion as under

- Re-evaluation of technical bids of Pegylated Interferons alpha 2a was done. The committee is of opinion that Gold Standard in alpha 2a is the one of Roche Pharma. The other drugs in this class quoted by Getz Pharma and by Hilton Pharma has no Sustained Virological Response (SVR) data published in any reputable medical journal regarding safety, efficacy and potency of this product.
- Only abstracts in national and international conferences has been presented by Getz Pharma

Following applied for the tender:

- Pegylated Interferon 2a 180 mcg 40 kDa by Roche
- Pegylated Interferon 2a 180 mcg 40 kDa by Pooyesh Daraon Co, Tehran, Iran
- Pegylated Interferon 2a 180 mcg 40 kDa by Hilton
- Pegylated Interferon 2a 180 mcg 20 kDa by Getz

In view of these observations technical committee is of view that among the participating bidders, the following two qualifies the technical, safety, efficacy and potency criteria

- Pegylated Interferon 2a 180 mcg 40 kDa by Roche
- Pegylated Interferon 2a 180 mcg 40 kDa by Pooyesh Daraon Co, Tehran, Iran

Value for money will be to buy Gold Standard in this class.

01 Dr. Hassan Murad Shah
Director General Health Services Sindh Hyderabad.

Chairman

02 Dr. M. Sabir Memon
Additional Secretary (PM & I)
Government of Sindh Health Department Karachi

Member

03 Dr. Abdul Khalique Shaikh
Program Manager
Prevention & Control of Hepatitis (Chief Minister Initiative) Sindh Hyderabad

Secretary/Member

04 Dr. Bader Faiyaz Zuberi
Professor of Medicines and Provincial Hepatologist
Civil Hospital Karachi

Member

05 Dr. Bikha Ram Devrajani
Professor of Medicine/Hepatologist, LUMHS, Jamshoro

Member

06 Mr. Habib-ul-Islam
Representative of Finance Department
Government of Sindh
Karachi

Member

07 Mr. Aziz Mustafa Shaikh
Assistant Accounts Officer
District Accounts Officer
Hyderabad

Member

52312/12/AJ

IN THE HONOURABLE HIGH COURT OF SINDH AT KARACHI
(ORIGINAL CIVIL JURISDICTION)

Suit No. 980 of 2015

M/s. Getz Pharma (Pvt.) Limited,
through its authorized person
a company incorporated under the
laws of Pakistan, registered office
at 29-30/27, Korangi Industrial Area,
Karachi-74900.....Plaintiff

Versus

1. Province of Sindh,
Through Chief Secretary,
Government of Sindh,
Having its office at
Sindh Secretariat,
Karachi
2. Province of Sindh
Through the Secretary,
Ministry of Health,
Government of Sindh,
Having its office at
Sindh Secretariat,
Karachi

Director General
Health Services,
Government of Sindh,
Having its office at D.G. Health Building,
Old Wahadat Colony,
Hyderabad
4. Programme Manager,
Prevention & Control of Hepatitis, Sindh,
(Chief Minister's Initiative),
Having its office at D.G. Health Building,
Old Wahadat Colony,
Hyderabad
5. Roche Pakistan Limited
Through their Managing Director,
A company incorporated under the
Laws of Pakistan, registered office
at 37-C, Block-6, P.E.C.H.S.,
Karachi
6. A.J. Mirza Pharma (Pvt.) Ltd,
Through its Managing Director,
A company incorporated under the
Laws of Pakistan, registered office
At First Floor, Shafi Court,
Merewether Road, Civil Lines,
Karachi

1096



- 7. Muhammad Arshad Awan,
Doing business in the name and
style of 'M/s. Lab Link Enterprises',
Office at M-1, Ammeer Terrace,
Near Civil Hospital.
Hyderabad

- 8. Schering-Plough Pakistan (Pvt.) Ltd.,
Through its Chief Executive,
A company incorporated under the
Laws of Pakistan, registered office
At 1-10, 2nd Floor, Executive Center,
I-8 Markaz,
Islamabad

- 9. Sindh Public Procurement Regulatory Authority
Through the Managing Director,
Offices at Barrack-8, Secretariat 4A,
Court Road, Karachi.....Defendants

SUIT FOR DECLARATION, PERMANENT INJUNCTION AND
DAMAGES



[A large, faint, handwritten signature or scribble is present across the lower half of the page.]

Order Sheet
 IN THE HIGH COURT OF SINDH KARACHI
 Suit No. 980 of 2015

Date	Order with Signature of Judge
------	-------------------------------

1. For orders on CMA No.9129/2015 :
2. For orders on CMA No.9130/2015 :

09.06.2015 :

Mr. Faisal Siddiqui advocate for the plaintiff

1. Urgency granted.
2. Issue notice to the defendants as well as to the learned Advocate General Sindh for 23.06.2015. Till the next date of hearing, ad-interim orders granted as prayed for.



[Handwritten signature]

[Handwritten signature: S. Nadeem]
 ATTEST,
[Handwritten signature]
 JUDGE

Ndm

CERTIFIED TO BE TRUE COPY

12th June 2015

COPY SUPPLIED TO
 DEFENDANT
 DEFENDANT'S COUNSEL
 COPY MADE READY ON
 12-06-2015
 COPY CHECKED ON
 13-06-2015
 COPY FILED IN
 BOOK NO. _____
 PAGE NO. _____
 ORIGINAL FILED IN
 BOOK NO. _____
 PAGE NO. _____

REGISTRAR

[Handwritten signature]
 12/6/15
 ASSISTANT REGISTRAR

[Large handwritten signature]
 22/06/15

[Handwritten signature]
 22/6/15
 ASSISTANT REGISTRAR